Focus: Penumbra is a public medical device company specializing in minimally-invasive vascular and surgical devices for acute cardiovascular and neurovascular conditions. With $1.1B in FY2025 revenue, it is a established player in interventional device markets.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Growing — net +17 jobs in 30d
40 jobs added vs 23 removed. Steady team buildout.
Penumbra is ideal for commercial, supply chain, and operational career tracks in a high-growth medical device company, but less suitable for pharma scientists seeking early-stage drug discovery roles.
Help build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Penumbra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: DiaMedica Therapeutics Inc. (DMAC) (CIK 0001401040) — EXHIBIT 99.1
EXHIBIT 99.1
Boston Scientific unveils major restructuring, plots job cuts amid savings drive - Fierce Biotech
Boston Scientific unveils major restructuring, plots job cuts amid savings drive Fierce Biotech
Penumbra (PEN) Starts The FORWARD Study, Is The Stock Already Expensive? - simplywall.st
Penumbra (PEN) Starts The FORWARD Study, Is The Stock Already Expensive? simplywall.st
Top 10 medtech deals in the first half of 2026 - MedTech Dive
Top 10 medtech deals in the first half of 2026 MedTech Dive
Penumbra wins CE mark for Thunderbolt clot removal tech - MedTech Dive
Penumbra wins CE mark for Thunderbolt clot removal tech MedTech Dive
CE Mark Granted to Penumbra's CAVT Platform - dicardiology.com
CE Mark Granted to Penumbra's CAVT Platform dicardiology.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Standardized approach to direct first pass aspiration technique for endovascular thrombectomy: Description and initial experience with CANADAPT.
US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo